Mining GEO and TCGA Database for Immune Microenvironment of Lung Squamous Cell Carcinoma Patients With or Without Chemotherapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Feb 25

PMID 35211415

Authors

Huiping Qiang

Jiaqi Li

Qing Chang

Yinchen Shen

Jialin Qian

Tianqing Chu

Affiliations

Soon will be listed here.

Abstract

Background: Chemotherapy is the main treatment for patients with lung squamous cell carcinoma (LUSC). However, how chemotherapy affects their immune system is rarely reported. This study was aimed to compare the differences in the immune microenvironment of LUSC patients with or without chemotherapy.

Methods: A total of 494 LUSC samples were obtained from The Cancer Genome Atlas (TCGA) database. The immune cell infiltration was evaluated by the ssGSEA algorithm, and the tumor subtype was assayed by ConsensusClusterPlus. The differences in tumor mutation burden (TMB) and clinical information between the two types were then compared. Additionally, the differentially expressed genes (DEGs) between two types were analyzed and hub genes were validated in the GEO database.

Results: LSCC samples in TCGA were divided into three subtypes. Then, combining the tumor subtype and immune scores, the samples were divided into hot and cold tumors. Regardless of whether LUSC patients received chemotherapy, the survival of the hot tumor group was not significantly prolonged compared with that of the cold tumor group. For LUSC patients who received chemotherapy, the TMB value in hot tumor group was significantly higher. Total 501 DEGs were identified between two groups. The high expressions of hub genes , , , , , etc. were also validated in the GSE37745 dataset.

Conclusion: Chemotherapy does not affect the survival and prognosis of LUSC patients, but it significantly increases the TMB value of patients with hot tumor. The DEGs, especially hub genes, such as , , and , may serve as biomarkers to distinguish cold and hot tumors in LUSC.

Citing Articles

mA-Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma.

Fan W, Huang J, Tian F, Hong X, Zhu K, Zhan Y Adv Sci (Weinh). 2024; 11(47):e2404609.

PMID: 39555714 PMC: 11653629. DOI: 10.1002/advs.202404609.

The MCIB Model: A Novel Theory for Describing the Spatial Heterogeneity of the Tumor Microenvironment.

Guo M, Sun Y, Wang X, Wang Z, Yuan X, Chen X Int J Mol Sci. 2024; 25(19).

PMID: 39408814 PMC: 11476373. DOI: 10.3390/ijms251910486.

Identification and validation of a novel robust glioblastoma prognosis model based on bioinformatics.

Zhang L, Yan X, Wang Y, Wang Q, Yan H, Yan Y Heliyon. 2024; 10(18):e37374.

PMID: 39309926 PMC: 11414505. DOI: 10.1016/j.heliyon.2024.e37374.

Significance of as a biomarker for clinical prognosis, immune infiltration, and drug therapy in lung squamous cell carcinoma.

Lin H, Wang J, Shi Q, Wu M PeerJ. 2024; 12:e17338.

PMID: 38708353 PMC: 11069361. DOI: 10.7717/peerj.17338.

Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.

Zhang Y, Chen Z, Liu Y, Han L, Jiang W, Wang Q Cancer Med. 2024; 13(7):e7175.

PMID: 38597130 PMC: 11004905. DOI: 10.1002/cam4.7175.

References

Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M . Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 2012; 19(1):194-204. DOI: 10.1158/1078-0432.CCR-12-1139. View

Takai T . Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002; 2(8):580-92. DOI: 10.1038/nri856. View

Pan H, Lu L, Cui J, Yang Y, Wang Z, Fan X . Immunological analyses reveal an immune subtype of uveal melanoma with a poor prognosis. Aging (Albany NY). 2020; 12(2):1446-1464. PMC: 7053626. DOI: 10.18632/aging.102693. View

Beck J, Ismail A, Tolomeo C . Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev. 2014; 40(8):980-9. DOI: 10.1016/j.ctrv.2014.06.006. View

Eisen M, Spellman P, Brown P, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-8. PMC: 24541. DOI: 10.1073/pnas.95.25.14863. View

Barclay A, van den Berg T . The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2013; 32:25-50. DOI: 10.1146/annurev-immunol-032713-120142. View

Szklarczyk D, Morris J, Cook H, Kuhn M, Wyder S, Simonovic M . The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2016; 45(D1):D362-D368. PMC: 5210637. DOI: 10.1093/nar/gkw937. View

Zhang X, Ren L, Yan X, Shan Y, Liu L, Zhou J . Identification of immune-related lncRNAs in periodontitis reveals regulation network of gene-lncRNA-pathway-immunocyte. Int Immunopharmacol. 2020; 84:106600. DOI: 10.1016/j.intimp.2020.106600. View

Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng Z . RNA-seq analyses of multiple meristems of soybean: novel and alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 2014; 14:169. PMC: 4070088. DOI: 10.1186/1471-2229-14-169. View

10.

Wang P, Wang Y, Hang B, Zou X, Mao J . A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget. 2016; 7(34):55343-55351. PMC: 5342421. DOI: 10.18632/oncotarget.10533. View

11.

Bailey M, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A . Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018; 173(2):371-385.e18. PMC: 6029450. DOI: 10.1016/j.cell.2018.02.060. View

12.

Jabs V, Edlund K, Konig H, Grinberg M, Madjar K, Rahnenfuhrer J . Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. PLoS One. 2017; 12(11):e0187246. PMC: 5675410. DOI: 10.1371/journal.pone.0187246. View

13.

Zhang C, Li Z, Qi F, Hu X, Luo J . Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma. Ann Transl Med. 2020; 7(22):648. PMC: 6944593. DOI: 10.21037/atm.2019.10.84. View

14.

Gu C, Pan X, Wang R, Li Y, Shen X, Shi J . Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component. Oncotarget. 2016; 7(17):24596-603. PMC: 5029726. DOI: 10.18632/oncotarget.8258. View

15.

Mawby W, Holmes C, Anstee D, Spring F, Tanner M . Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J. 1994; 304 ( Pt 2):525-30. PMC: 1137523. DOI: 10.1042/bj3040525. View

16.

Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin K . Tumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer. Front Immunol. 2019; 10:2368. PMC: 6811516. DOI: 10.3389/fimmu.2019.02368. View

17.

Chen J, Gu C, Chen X, Dai C, Zhao S, Xie H . Clinicopathological and prognostic analyses of 86 resected pulmonary lymphoepithelioma-like carcinomas. J Surg Oncol. 2020; 123(2):544-552. DOI: 10.1002/jso.26276. View

18.

Melendez B, Van Campenhout C, Rorive S, Remmelink M, Salmon I, DHaene N . Methods of measurement for tumor mutational burden in tumor tissue. Transl Lung Cancer Res. 2018; 7(6):661-667. PMC: 6249625. DOI: 10.21037/tlcr.2018.08.02. View

19.

Li B, Cui Y, Nambiar D, Sunwoo J, Li R . The Immune Subtypes and Landscape of Squamous Cell Carcinoma. Clin Cancer Res. 2019; 25(12):3528-3537. PMC: 6571041. DOI: 10.1158/1078-0432.CCR-18-4085. View

20.

Kersten K, Salvagno C, de Visser K . Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol. 2015; 6:516. PMC: 4595807. DOI: 10.3389/fimmu.2015.00516. View